SEC Form 4 · accession 0000950138-19-000129
Elanco Animal Health Inc · ELAN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
R David Hoover
Director
Period of report
Mar 11, 2019
Accepted (ET)
Mar 13, 2019 · 5:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001739104
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 11, 2019 | P$0 | 920 | — | A | 920 | I | Suzanne A. Hoover Revocable Trust |
| Common Stock | holding | — | — | — | 11,796 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On March 11, 2019, Eli Lilly and Company ("Lilly") announced the completion of its offer to exchange shares of Lilly common stock for all of the common stock of the Issuer owned by Lilly (the "Exchange Offer"). The Reporting Person tendered 1,500 shares of Lilly common stock in the Exchange Offer, which shares were subject to a proration factor of 13.5970839%. As a result, the Reporting Person received 920 shares of Issuer common stock in exchange for 204 shares of Lilly common stock accepted in the Exchange Offer, based on an exchange ratio of 4.5121 shares of Issuer common stock for each share of Lilly common stock accepted.
Remarks
Chairman of the Elanco Board of Directors